(生物谷Bioon.com) 原文出处:Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和...
在24周的盲法治疗期间,IMU-838治疗组的退出率仅为4.3%,而安慰剂组为7.2%。 原文出处:Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020 以上是关于(下...